Evidence map›Paper›PMID 41477409›Full record

ArticleCureus2025

Bridging Haemato-Oncology and Critical Care: Survival and Functional Outcomes From a Portuguese Central Hospital.

Diana Martins Fernandes, André Airosa Pardal, Paula Ferraz, Rita Queirós Pereira, Marisa Simões, Marta Henriques, Francisco Dias, André Valois, Patrícia Rocha Silva, Lúcia Meireles Brandão and 4 more

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Diana Martins FernandesIntensive Care Medicine, Unidade Local de Saúde de São João, Porto, PRT.
André Airosa PardalHaemato-Oncology, Unidade Local de Saúde de São João, Porto, PRT.
Paula FerrazPharmacology, Unidade Local de Saúde de São João, Porto, PRT.
Rita Queirós PereiraImmunotherapy, Unidade Local de Saúde de São João, Porto, PRT.
Marisa SimõesIntensive Care Medicine, Unidade Local de Saúde de Matosinhos, Porto, PRT.
Marta HenriquesHaemato-Oncology, Unidade Local de Saúde de São João, Porto, PRT.
Francisco DiasIntensive Care Medicine, Unidade Local de Saúde de São João, Porto, PRT.
André ValoisPharmacology, Unidade Local de Saúde de São João, Porto, PRT.
Patrícia Rocha SilvaHaemato-Oncology, Unidade Local de Saúde de São João, Porto, PRT.
Lúcia Meireles BrandãoIntensive Care Medicine, Unidade Local de Saúde de São João, Porto, PRT.
Guiomar CastroIntensive Care Medicine, Unidade Local de Saúde de São João, Porto, PRT.
Marta CoutoIntensive Care Medicine, Unidade Local de Saúde de São João, Porto, PRT.
José Artur PaivaIntensive Care Medicine, Unidade Local de Saúde de São João, Porto, PRT.
Nuno PríncipeIntensive Care Medicine, Unidade Local de Saúde de São João, Porto, PRT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background  Despite substantial therapeutic progress in haemato-oncology (HO), referring exclusively to patients with haematological malignancies, ICU admission decisions for these patients are often hindered by the perception of poor prognosis. This study aimed to evaluate the one-year survival and functional outcomes of critically ill HO patients following hospital discharge. Methods  A retrospective, single-centre observational study was conducted in a Portuguese tertiary care centre, including 54 consecutive non-elective ICU admissions of adult HO patients between January 2022 and October 2023. The primary endpoint was one-year survival post-hospital discharge, while secondary endpoints included maintenance of treatment plans and functional recovery assessed using the Eastern Cooperative Oncology Group (ECOG) performance status one year after hospital discharge. Results  Seventy-four percent of patients survived their ICU stay, with survival rates of 61% at six months and 50% at one year post-discharge. Among one-year survivors, 93% exhibited good performance status (ECOG 0-1) and continued their intended oncological treatment. Only 7% transitioned to palliative care. Despite a high burden of organ dysfunction (87% with multiple dysfunctions) and significant therapeutic needs, including mechanical ventilation (33%) and renal replacement therapy (50%), functional recovery and treatment resumption were achieved in most survivors. Conclusions  Critically ill HO patients can achieve meaningful survival and functional recovery following ICU admission. The findings challenge prior biases against ICU admissions for this population and underscore the need for early, multidisciplinary intervention to optimize outcomes.

Indexed as

haematology malignancyhaemato-oncologyintensive care unitperformance statussurvival

Identifiers

PMID41477409
PMCPMC12750398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.